Embecta Corp. Overview
Pro stress-test →Embecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and approximately 2,000 employees around the globe. The company is focused on transforming into a broad-based medical supplies company which serves chronic care patients and drug delivery partners while maintaining its global leadership position in core injection products and expanding its product portfolio.
Strategic Profile
Pro stress-test →Embecta is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes, primarily selling to wholesalers and distributors. The company is strengthening its core business through its brand transition program in international markets, expecting significant completion by the end of calendar year 2026.
Competitive Landscape
Pro stress-test →As a medical device company providing diabetes care solutions in the U.S. and internationally, Embecta competes primarily against established medical device manufacturers in the insulin delivery and blood glucose monitoring space. The company faces competition from larger, diversified healthcare companies as well as specialized diabetes care providers. Competition and lower U.S. pricing from customers are creating headwinds in the American market, though international markets remain a bright spot.
Industry Context
Embecta Corp. operates in Medical Devices - Diabetes Care / Insulin Delivery.
Key facts
Founded: 1924 · Headquarters: Parsippany, NJ · Employees: 2,000 · Revenue: $1.1B